Skip navigation
Speakers

Achieve ADF Labeling • Reduce Abuse Potential • Integrate Technologies to Support Deterrence

March 7-8, 2017
  • Alexandria, VA

David Baker
Chief Commercial Officer
Alcobra Inc.

Dan Cohen
Executive Vice President, Government & Public Relations, KemPharm;
Chair, Abuse Deterrent Coalition Forum

Richard Dart, MD
Director
Rocky Mountain Poison and Drug Center

Gregg DeRosa
Vice President, Global Clinical R&D Global Generic Medicines
Teva Pharmaceuticals

Candis Edwards
Senior Vice President, Clinical Regulatory Affairs
Amneal Pharmaceuticals

Paul Eiting
Senior Manager, Office of Policy and Representation
Blue Cross Blue Shield

Torben Elhauge
Senior Science Specialist
Egalet Corp.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP
Adjunct Associate Professor, Pharmacy Practice & Pain Management
Albany College of Pharmacy & Health Sciences

Mark Hendrickson
Senior Director, Sciences and Regulatory Affairs
Association for Accessible Medicines (AAM)

Shruti Kulkarni, JD
Policy Director
Center for Lawful Access and Abuse Deterrence (CLAAD)

Alexander Kraus
Vice President Product Development, Technical and Government Affairs
Grünenthal USA

Penny Levin
Director, Global Regulatory Intelligence and Policy
Teva Pharmaceuticals

Karsten Lindhardt
Senior Vice President R&D, Site Management
Egalet Corp.

Isa Odidi, PhD, DSc, MBA
Chief Executive Officer
IntelliPharmaCeutics International Inc.

Peter Pitts
President & Co Founder
Center for Medicine in the Public Interest

Brandon C. Presley
Team Leader, Abuse Deterrent Formulations (ADF)
NMS Labs

Jon Rodis
Patient Advocate Living with Marfan Syndrome
Global Patient Advocate

Beatrice Setnik, PhD
Vice President Scientific Affairs, Early Phase
INC Research

Greg Sturmer
President and CEO
Elysium Therapeutics

Douglas Throckmorton, MD
Deputy Center Director, Regulatory Programs
U.S. Food and Drug Administration

Lynn Webster, MD
Past President
American Academy of Pain Medicine

David Baker
Chief Commercial Officer
Alcobra Inc.

Dan Cohen
Executive Vice President, Government & Public Relations, KemPharm;
Chair, Abuse Deterrent Coalition Forum

Richard Dart, MD
Director
Rocky Mountain Poison and Drug Center

Gregg DeRosa
Vice President, Global Clinical R&D Global Generic Medicines
Teva Pharmaceuticals

Candis Edwards
Senior Vice President, Clinical Regulatory Affairs
Amneal Pharmaceuticals

Paul Eiting
Senior Manager, Office of Policy and Representation
Blue Cross Blue Shield

Torben Elhauge
Senior Science Specialist
Egalet Corp.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP
Adjunct Associate Professor, Pharmacy Practice & Pain Management
Albany College of Pharmacy & Health Sciences

Mark Hendrickson
Senior Director, Sciences and Regulatory Affairs
Association for Accessible Medicines (AAM)

Shruti Kulkarni, JD
Policy Director
Center for Lawful Access and Abuse Deterrence (CLAAD)

Alexander Kraus
Vice President Product Development, Technical and Government Affairs
Grünenthal USA

Penny Levin
Director, Global Regulatory Intelligence and Policy
Teva Pharmaceuticals

Karsten Lindhardt
Senior Vice President R&D, Site Management
Egalet Corp.

Isa Odidi, PhD, DSc, MBA
Chief Executive Officer
IntelliPharmaCeutics International Inc.

Peter Pitts
President & Co Founder
Center for Medicine in the Public Interest

Brandon C. Presley
Team Leader, Abuse Deterrent Formulations (ADF)
NMS Labs

Jon Rodis
Patient Advocate Living with Marfan Syndrome
Global Patient Advocate

Beatrice Setnik, PhD
Vice President Scientific Affairs, Early Phase
INC Research

Greg Sturmer
President and CEO
Elysium Therapeutics

Douglas Throckmorton, MD
Deputy Center Director, Regulatory Programs
U.S. Food and Drug Administration

Lynn Webster, MD
Past President
American Academy of Pain Medicine